Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema
Conclusion
After adjusting for baseline characteristics, the difference in letters gained between patients receiving ranibizumab versus aflibercept was non-significant across trials, highlighting the importance of adjusting for baseline characteristics in future comparisons.
Funding
Novartis Pharma AG.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Clinical Trials | Diabetes | Drugs & Pharmacology | Endocrinology | Lucentis | Pharmaceuticals | Ranibizumab Injection | Study